Molecular Profile Detail

Profile Name BRAF G466V
Gene Variant Detail

BRAF G466V (loss of function)

Relevant Treatment Approaches MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor LY3009120

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
Clinical Trial Phase Therapies Title Recruitment Status
NCT03843775 Phase Ib/II Binimetinib + Encorafenib A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers Recruiting
NCT03839342 Phase II Binimetinib + Encorafenib Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER) Recruiting
NCT02318901 Phase Ib/II Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer Terminated
NCT02138292 Phase I Digoxin + Trametinib A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma Completed
NCT02508077 Phase II Fluorouracil + Irinotecan + Leucovorin Panitumumab FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Terminated
NCT03181100 Phase II Nab-paclitaxel Paclitaxel Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas Recruiting
NCT03149029 Phase II Dabrafenib + Pembrolizumab + Trametinib Pembrolizumab + Trametinib Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma Recruiting
NCT02130466 Phase Ib/II Dabrafenib + Trametinib Pembrolizumab + Trametinib Dabrafenib + Pembrolizumab Dabrafenib + Pembrolizumab + Trametinib A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022) Active, not recruiting
NCT01138085 Phase I Trametinib + Uprosertib Safety, Pharmacokinetics (PK) of AKT and MEK Combination Completed
NCT01802320 Phase II MK2206 Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Unknown status
NCT02785068 Phase I Fluorouracil + Irinotecan + Leucovorin + MM-151 Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer Withdrawn
NCT03069950 Phase II Dexamethasone + Floxuridine + Fluorouracil + Irinotecan + Leucovorin + Panitumumab Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver Withdrawn
NCT03384940 Phase II DS-8201a DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer Recruiting
NCT03457896 Phase II Cetuximab + Neratinib Neratinib + Trastuzumab Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status Recruiting
NCT01960023 Phase Ib/II Cetuximab + Neratinib Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer Withdrawn
NCT03978611 Phase I Ipilimumab + Relatlimab A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment Not yet recruiting
NCT02065063 Phase I Palbociclib + Trametinib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors Completed
NCT01941927 Phase II Trametinib + Uprosertib Trametinib With GSK2141795 in BRAF Wild-type Melanoma Unknown status
NCT03580382 Phase Ib/II CDX-3379 + Trametinib Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma Recruiting
NCT03581292 Phase II Temozolomide + Veliparib Veliparib, Radiation Therapy, and Temozolomide in Treating Participants With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600E Mutations Recruiting
NCT03693170 Phase II Binimetinib + Cetuximab + Encorafenib encorAfenib, biNimetinib and Cetuximab in Subjects witH previOusly Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC) Recruiting
NCT02693535 Phase II Cobimetinib + Vemurafenib Regorafenib Pembrolizumab Temsirolimus Dasatinib Pertuzumab + Trastuzumab Ipilimumab + Nivolumab Crizotinib Palbociclib Sunitinib Olaparib Cetuximab TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Recruiting
NCT03973918 Phase II Binimetinib + Encorafenib Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF) Not yet recruiting
NCT01750918 Phase II Fluorouracil Dabrafenib + Panitumumab Dabrafenib + Panitumumab + Trametinib Panitumumab + Trametinib BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) Active, not recruiting
NCT03189030 Phase I pLADD Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer Active, not recruiting
NCT01711632 Phase II Vemurafenib BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia Active, not recruiting
NCT01748149 Phase I Vemurafenib Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas Active, not recruiting
NCT02949843 Phase II Nivolumab + Pembrolizumab Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations Active, not recruiting
NCT01897116 Phase I Hydroxychloroquine + Vemurafenib A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma Completed
NCT03224767 Phase II Cobimetinib + Vemurafenib Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma Recruiting
NCT04017650 Phase Ib/II Cetuximab + Encorafenib + Nivolumab Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer Recruiting
NCT02034110 Phase II Dabrafenib + Trametinib Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Active, not recruiting
NCT03915951 Phase II Binimetinib + Encorafenib An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer Recruiting
NCT01721603 Phase II Dabrafenib A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases Terminated
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed
NCT02915666 Phase I Dabrafenib + Digoxin + Trametinib A Clinical Trial of Patients With Melanoma Withdrawn
NCT03475004 Phase II Bevacizumab + Binimetinib + Pembrolizumab Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer Recruiting
NCT01740648 Phase I Fluorouracil + Trametinib Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer Active, not recruiting
NCT02164916 Phase II Cetuximab + Irinotecan Cetuximab + Irinotecan + Vemurafenib S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer Active, not recruiting
NCT03975231 Phase I Dabrafenib + Trametinib Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer Not yet recruiting
NCT02382549 Phase Ib/II 6MHP vaccine + Dabrafenib + Trametinib A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (Mel61) Recruiting
NCT01534897 Phase I Dabrafenib Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 Completed
NCT01709292 Phase II Vemurafenib Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer Active, not recruiting
NCT03365882 Phase II Cetuximab + Irinotecan Pertuzumab + Trastuzumab S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT01089101 Phase Ib/II Selumetinib Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma Recruiting
NCT03668431 Phase II Dabrafenib + Spartalizumab + Trametinib Dabrafenib + Trametinib + PDR001 In Colorectal Cancer Recruiting
NCT02367859 Phase II Dabrafenib + Trametinib Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma Active, not recruiting
NCT03255083 Phase I DS-1205c + Osimertinib DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Recruiting
NCT01876641 Phase Ib/II Decitabine + Vemurafenib Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Terminated
NCT03840915 Phase Ib/II Cisplatin + M7824 + Pemetrexed Docetaxel + M7824 Carboplatin + M7824 + Pemetrexed Cisplatin + Gemcitabine + M7824 Carboplatin + Gemcitabine + M7824 Carboplatin + M7824 + Nab-paclitaxel M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT02465060 Phase II Erdafitinib Copanlisib Trametinib Crizotinib Sunitinib Sapanisertib Nivolumab AZD4547 Dasatinib Pertuzumab + Trastuzumab Dabrafenib + Trametinib Binimetinib Adavosertib Osimertinib Palbociclib Afatinib Capivasertib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Larotrectinib Taselisib Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting
NCT02257424 Phase Ib/II Trametinib The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma Recruiting
NCT01638676 Phase Ib/II Metformin + Vemurafenib A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients Unknown status
NCT03631706 Phase II M7824 Pembrolizumab M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT01754376 Phase II Aldesleukin + Vemurafenib Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma Terminated
NCT02928224 Phase III Cetuximab + Encorafenib Binimetinib + Cetuximab + Encorafenib Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC) Active, not recruiting
NCT01726738 Phase II Dabrafenib + Trametinib LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations Completed
NCT03732703 Phase Ib/II Dexamethasone + Enasidenib + Ixazomib + Pomalidomide Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide Dexamethasone + Ixazomib + Pomalidomide + Venetoclax Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide Daratumumab + Dexamethasone + Ixazomib + Pomalidomide Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG) Recruiting
NCT03639714 Phase Ib/II GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab A Study of a Personalized Neoantigen Cancer Vaccine Recruiting
NCT03864042 Phase I Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole Modafinil Bupropion + Rosuvastatin Binimetinib + Encorafenib Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors Recruiting
NCT01943422 Phase Ib/II Interferon alpha-2b + Vemurafenib Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma Completed
NCT02143050 Phase Ib/II Dabrafenib + Metformin + Trametinib Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients Recruiting
NCT01336634 Phase II Dabrafenib Dabrafenib + Trametinib Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. Active, not recruiting
NCT03260491 Phase I U3-1402 U3-1402 in Metastatic or Unresectable EGFR-mutant Non-Small Cell Lung Cancer Recruiting
NCT01765543 Phase I Rifampin + Vemurafenib A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy Completed
NCT02285439 Phase Ib/II Binimetinib Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors Recruiting
NCT03665129 Phase I Durvalumab + IPH5401 IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001) Recruiting
NCT01586195 Phase II Vemurafenib Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E Terminated
NCT01596140 Phase I Temsirolimus + Vemurafenib Everolimus + Vemurafenib Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer Active, not recruiting
NCT03310541 Phase I Capivasertib Capivasertib + Enzalutamide Capivasertib + Fulvestrant AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations Recruiting
NCT02012231 Phase Ib/II PLX8394 Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. Terminated
NCT03516981 Phase II MK-4280 + Pembrolizumab Lenvatinib + Pembrolizumab A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495) Recruiting
NCT01713972 Phase I Dabrafenib + Pazopanib Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors Completed
NCT02140840 Phase II Trametinib A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib Withdrawn
NCT02587650 Phase II Ceritinib Capmatinib Regorafenib Entrectinib Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Completed
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting
NCT03429803 Phase Ib/II MLN2480 TAK-580 In Gliomas and Other Tumors Recruiting
NCT03114319 Phase I TNO155 Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors Recruiting
NCT03088176 Phase I Dabrafenib + Talimogene laherparepvec + Trametinib Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma Recruiting
NCT01636622 Phase I Carboplatin + Paclitaxel + Vemurafenib Study of Vemurafenib, Carboplatin, and Paclitaxel Active, not recruiting
NCT02097225 Phase I Dabrafenib + Onalespib + Trametinib Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma That is Metastatic or Cannot be Removed by Surgery Active, not recruiting
NCT01767454 Phase I Dabrafenib + Ipilimumab + Trametinib Dabrafenib + Ipilimumab Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma Completed
NCT01781026 Phase II Vemurafenib Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases Completed
NCT03455764 Phase Ib/II Dabrafenib + MCS110 + Trametinib A Phase I/II Study of MCS110 With BRAF/MEK Inhibition in Patients With Melanoma After Progression on BRAF/MEK Inhibition Recruiting
NCT01585415 Phase I Vandetanib Vemurafenib and White Blood Cell Therapy for Advanced Melanoma Terminated
NCT03551626 Phase III Dabrafenib + Trametinib Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus) Recruiting
NCT02224781 Phase III Ipilimumab + Nivolumab Dabrafenib + Trametinib Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Recruiting
NCT01989585 Phase Ib/II Dabrafenib + Navitoclax + Trametinib Dabrafenib + Trametinib Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery Recruiting
NCT01657591 Phase I Vemurafenib + XL888 Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma Active, not recruiting
NCT02027961 Phase Ib/II Dabrafenib + Durvalumab + Trametinib Durvalumab + Trametinib Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone Completed
NCT01978236 Phase II Dabrafenib + Trametinib Dabrafenib Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites Terminated
NCT02427893 Phase III Cobimetinib Vemurafenib Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma Withdrawn
NCT03101254 Phase Ib/II Cobimetinib + LY3022855 + Vemurafenib LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma Recruiting
NCT02721459 Phase I Cobimetinib + Vemurafenib + XL888 XL888 + Vemurafenib + Cobimetinib for Unresectable B Rapidly Accelerated Fibrosarcoma (BRAF) Mutated Stage III/IV Melanoma Active, not recruiting
NCT01682213 Phase II Dabrafenib Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation Completed
NCT01512251 Phase Ib/II Buparlisib + Vemurafenib BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma Completed
NCT01682083 Phase III Dabrafenib + Trametinib A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. Active, not recruiting
NCT01909453 Phase III Vemurafenib Encorafenib Binimetinib + Encorafenib Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma Active, not recruiting
NCT01947023 Phase I Dabrafenib + Lapatinib Dabrafenib and Lapatinib Ditosylate in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT02818023 Phase I Pembrolizumab + Vemurafenib Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma Active, not recruiting
NCT03272464 Phase I Dabrafenib + Itacitinib + Trametinib Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. Recruiting
NCT01940809 Phase II Dabrafenib Trametinib Ipilimumab Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery Active, not recruiting
NCT01495988 Phase II Bevacizumab Vemurafenib Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma Terminated
NCT02196181 Phase II Dabrafenib + Trametinib Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Active, not recruiting
NCT02200562 Phase Ib/II Dabrafenib + Ipilimumab Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma Terminated
NCT03634982 Phase I RMC-4630 Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors Recruiting
NCT03989115 Phase Ib/II Cobimetinib + RMC-4630 Dose-Escalation and Dose-Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors Recruiting
NCT01514864 Phase II Dasatinib Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation Terminated
NCT02961283 Phase I ASN003 Study of ASN003 in Subjects With Advanced Solid Tumors Terminated
NCT03301636 Phase II Indoximod + Nivolumab Indoximod + Pembrolizumab A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma (NLG2107) Active, not recruiting
NCT02456701 Phase I CDX-3379 + Vemurafenib Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 Completed
NCT01659151 Phase II Fludarabine Vemurafenib Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma Active, not recruiting
NCT01787500 Phase I Cetuximab + Irinotecan + Vemurafenib Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers Active, not recruiting
NCT02091141 Phase II Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Recruiting
NCT01902173 Phase Ib/II Trametinib Dabrafenib + Uprosertib GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Suspended
NCT01820364 Phase II Binimetinib + Encorafenib Encorafenib + Ribociclib Buparlisib + Encorafenib BGJ398 + Encorafenib Capmatinib + Encorafenib LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma Terminated
NCT01739764 Phase III Vemurafenib An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol Active, not recruiting
NCT01677741 Phase I Dabrafenib The Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Pediatric Subjects Recruiting
NCT03793179 Phase III Carboplatin + Pembrolizumab + Pemetrexed Pembrolizumab + Pemetrexed Pembrolizumab Carboplatin + Pemetrexed Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer Recruiting
NCT01683188 Phase III Aldesleukin + Vemurafenib HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated
NCT03992456 Phase II Panitumumab Regorafenib trifluridine/tipiracil hydrochloride Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer Not yet recruiting
NCT03087071 Phase II Panitumumab Trametinib Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer Recruiting
NCT03543969 Phase I Cobimetinib + Vemurafenib Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma Recruiting
NCT03446157 Phase II Cetuximab + Palbociclib Palbociclib and Cetuximab in Metastatic Colorectal Cancer Recruiting
NCT02263898 Phase II Binimetinib + Encorafenib Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations Withdrawn
NCT01619774 Phase II Dabrafenib + Trametinib An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor Completed
NCT02967692 Phase III Dabrafenib + Spartalizumab + Trametinib Dabrafenib + Trametinib A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma Recruiting
NCT01844674 Phase I Tizanidine + Vemurafenib A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies Completed
NCT02145143 Phase I Vemurafenib Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib Active, not recruiting
NCT01907802 Phase I Dabrafenib Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction Terminated
NCT02974803 Phase II Dabrafenib + Trametinib Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases Active, not recruiting
NCT01656642 Phase I Atezolizumab + Vemurafenib A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma Active, not recruiting
NCT02230306 Phase II Cobimetinib + Vemurafenib Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases Terminated
NCT01524978 Phase II Vemurafenib Cetuximab A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers Completed
NCT03442569 Phase II Ipilimumab + Nivolumab + Panitumumab PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC Recruiting
NCT02039947 Phase II Dabrafenib + Trametinib Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain Completed
NCT01835184 Phase I Cabozantinib + Vemurafenib Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery Terminated
NCT02094872 Phase II Doxorubicin Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Active, not recruiting
NCT01436656 Phase I Encorafenib A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma Active, not recruiting
NCT02068079 Phase I Trientine + Vemurafenib A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma Withdrawn
NCT01954043 Phase I Dabrafenib + Rabeprazole + Rifampin A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors Completed
NCT03377361 Phase Ib/II Ipilimumab + Nivolumab Ipilimumab + Nivolumab + Trametinib An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread Recruiting
NCT01981187 Phase II Encorafenib LGX818 for Patients With BRAFV600 Mutated Tumors Completed
NCT03026517 Phase I Dabrafenib + Phenformin + Trametinib Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma Recruiting
NCT01701037 Phase II Dabrafenib + Trametinib Dabrafenib Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery Terminated
NCT03178851 Phase I Atezolizumab + Cobimetinib A Study Evaluating Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy Recruiting
NCT02908672 Phase III Cobimetinib + Vemurafenib Atezolizumab + Cobimetinib + Vemurafenib A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma Active, not recruiting
NCT01777776 Phase Ib/II Encorafenib Encorafenib + Ribociclib Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Terminated
NCT01843738 Phase I Vemurafenib Radiation Use During Vemurafenib Treatment Withdrawn
NCT03273153 Phase III Pembrolizumab Atezolizumab + Cobimetinib A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma Recruiting
NCT03005639 Phase II Cobimetinib + Vemurafenib ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma Withdrawn
NCT02296112 Phase II Trametinib Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations Active, not recruiting
NCT03911869 Phase II Binimetinib + Encorafenib An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS) Recruiting
NCT01813214 Phase II Vemurafenib The Effects of Vemurafenib on Immunity in Patients With Melanoma Terminated
NCT02906059 Phase I Adavosertib + Irinotecan Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer Recruiting
NCT01946789 Phase I ALT-803 A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors Completed
NCT01767623 Phase I Vemurafenib A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients Completed
NCT02428712 Phase Ib/II PLX8394 A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors Active, not recruiting
NCT02723006 Phase I MLN2480 + Nivolumab MLN1202 + Nivolumab Ipilimumab + Nivolumab + Vedolizumab Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma Terminated
NCT03592641 Phase II Savolitinib Volitinib in Treating Participants With MET Amplified Metastatic or Unresectable Colorectal Cancer Recruiting
NCT02159066 Phase II Binimetinib + Encorafenib + Ribociclib Binimetinib + Encorafenib Binimetinib + Capmatinib + Encorafenib Binimetinib + Buparlisib + Encorafenib BGJ398 + Binimetinib + Encorafenib LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma Active, not recruiting
NCT01826448 Phase I Pexidartinib + Vemurafenib A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma Terminated
NCT02145910 Phase I Vemurafenib Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases Withdrawn
NCT01603212 Phase Ib/II Aldesleukin + Alpha 2 Interferon + Vemurafenib Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor Completed
NCT01738451 Phase I Dabrafenib A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors Completed
NCT02036086 Phase II Cobimetinib + Vemurafenib Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases Recruiting
NCT03297606 Phase II Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) Recruiting
NCT01543698 Phase Ib/II Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors Active, not recruiting
NCT02278133 Phase Ib/II Cetuximab + Encorafenib + LGK974 Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations Completed
NCT02082665 Phase I Dabrafenib + Midazolam + Rosuvastatin Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam Completed
NCT01519323 Phase I Vemurafenib BRIM-P Terminated
NCT02124772 Phase I Trametinib Dabrafenib + Trametinib Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations Recruiting
NCT01974258 Phase I Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients Withdrawn
NCT01942993 Phase II Vemurafenib The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma Terminated
NCT03220035 Phase II Vemurafenib Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations Recruiting
NCT01894672 Phase II Encorafenib BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation Completed
NCT01877811 Phase Ib/II RXDX-105 CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 Completed
NCT02795156 Phase II Cabozantinib Afatinib Regorafenib Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Recruiting
NCT03664024 Phase II Pembrolizumab + Pemetrexed Carboplatin + Pembrolizumab + Pemetrexed Cisplatin + Pembrolizumab + Pemetrexed Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782) Active, not recruiting
NCT03353753 Phase III DCC-2618 Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus) Active, not recruiting
NCT02747537 Phase II Irinotecan + Sorafenib Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan Recruiting
NCT03396497 Phase I LYC-55716 + Pembrolizumab Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer Recruiting
NCT01841463 Phase Ib/II Vemurafenib + Voruciclib Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation Suspended
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting
NCT01449058 Phase Ib/II Alpelisib + Binimetinib A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors Completed
NCT02974725 Phase I LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254 A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma Recruiting
NCT01231594 Phase I Dabrafenib Trametinib A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors Completed
NCT03415126 Phase I ASN007 A Study of ASN007 in Patients With Advanced Solid Tumors Recruiting
NCT01723202 Phase II Dabrafenib + Trametinib Dabrafenib Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Active, not recruiting
NCT02648490 Phase I Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron HLX07 An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers Recruiting
NCT01531361 Phase I Crizotinib Sorafenib + Vemurafenib Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer Active, not recruiting
NCT03972046 Phase II Dabrafenib + Talimogene laherparepvec + Trametinib Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma Recruiting
NCT02610361 Phase I BGB-283 Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors Completed
NCT02860780 Phase I Prexasertib + Ralimetinib A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer Completed
NCT03218826 Phase I AZD8186 + Docetaxel PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Recruiting
NCT03555149 Phase Ib/II Atezolizumab Atezolizumab + Isatuximab Atezolizumab + Bevacizumab + PGG beta-glucan A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) Recruiting
NCT01885195 Phase II Binimetinib MEK162 for Patients With RAS/RAF/MEK Activated Tumors Completed
NCT02050321 Phase II Acitretin + Vemurafenib A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma Terminated
NCT01744652 Phase I Crizotinib + Dasatinib Dasatinib and Crizotinib in Advanced Cancer Completed
NCT03696212 Phase Ib/II Grapiprant + Pembrolizumab Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma Recruiting
NCT01781429 Phase Ib/II Ulixertinib Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies Completed
NCT03391232 Phase I PolyPEPI1018 Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Metastatic Colorectal Cancer (OBERTO) Active, not recruiting
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT01719380 Phase Ib/II Cetuximab + Encorafenib Alpelisib + Cetuximab + Encorafenib Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Completed
NCT03051035 Phase I KO-947 First-in-Human Study of KO-947 in Non-Hematological Malignancies Recruiting
NCT01306045 Phase II Erlotinib Lapatinib MK2206 Sunitinib Selumetinib Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Recruiting
NCT03162627 Phase I Olaparib + Selumetinib Selumetinib and Olaparib in Solid Tumors Recruiting
NCT03784378 Phase I RXDX-105 Continued Access to RXDX-105 Recruiting
NCT03213691 Phase II Selumetinib Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT02857270 Phase I LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Recruiting
NCT01037790 Phase II Palbociclib PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Recruiting
NCT03091257 Phase I Dabrafenib + Trametinib Dabrafenib Trametinib A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma Recruiting
NCT03559049 Phase Ib/II Carboplatin + Pembrolizumab + Pemetrexed + Rucaparib Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer Recruiting
NCT03332589 Phase I E6201 Study of E6201 for the Treatment of Central Nervous System Metastases (CNS) Recruiting